Literature DB >> 2878077

Synthesis and renal vasodilator activity of some dopamine agonist 1-aryl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diols: halogen and methyl analogues of fenoldopam.

J Weinstock, D L Ladd, J W Wilson, C K Brush, N C Yim, G Gallagher, M E McCarthy, J Silvestri, H M Sarau, K E Flaim.   

Abstract

Certain 6-halo-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines were found to be potent D-1 dopamine agonists. The 1-(4-hydroxyphenyl) analogues did not have central nervous system activity because their high polarity inhibited entry into the brain. However, these compounds were potent renal vasodilators. Fenoldopam, the 6-chloro analogue, is an especially significant member of the series, and its synthesis, pharmacology, and clinical properties have been studied extensively. The 6-methyl and 6-iodo congeners were potent renal vasodilators, but nonpotent partial D-1 agonists as measured by stimulation of rat caudate adenylate cyclase. A possible rationalization suggests different receptor reserves for these activities. The 9-substituted benzazepines were either inactive or of low potency as dopamine agonists, while the N-methyl analogues had significant antagonist potency as measured by inhibition of dopamine stimulation of rat caudate adenylate cyclase.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2878077     DOI: 10.1021/jm00161a029

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Synthesis and dopamine receptor pharmacological evaluations on ring C ortho halogenated 1-phenylbenzazepines.

Authors:  Rajan Giri; Hari K Namballa; Ananta Sarker; Ian Alberts; Wayne W Harding
Journal:  Bioorg Med Chem Lett       Date:  2020-06-04       Impact factor: 2.823

2.  Strategies for the Preparation of Differentially Protected ortho-Prenylated Phenols.

Authors:  Christophe Hoarau; Thomas R R Pettus
Journal:  Synlett       Date:  2003       Impact factor: 2.454

3.  Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease--the differential effects of D1 dopamine antagonists in the primate.

Authors:  K K Gnanalingham; A J Hunter; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

4.  Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset.

Authors:  K K Gnanalingham; D D Erol; A J Hunter; L A Smith; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

5.  The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease.

Authors:  K K Gnanalingham; A J Hunter; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

6.  Synthesis of Chiral Tetrahydro-3-benzazepine Motifs by Iridium-Catalyzed Asymmetric Hydrogenation of Cyclic Ene-carbamates.

Authors:  Bram B C Peters; Pher G Andersson; Somsak Ruchirawat; Winai Ieawsuwan
Journal:  Org Lett       Date:  2022-03-03       Impact factor: 6.005

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.